Citations

Clear

6273 citation(s) found for "To, Andrew".

Neuro-Ophthalmic Literature Review
Bellows, David A., Chen, John J. , Hung, Wei-Che , Vaphiades, Michael S., Chen, John J , Mak, Andrew C. Y. , Verma, Rashmi , Weber, Konrad Peter

Mayo Clinic

Neuro-Ophthalmology | June 24, 2024 | Volume: 48 | Issue: 4 | Pages: 310-314

10.1080/01658107.2024.2356494 Get It

Sculpting the future: A narrative review of 3D printing in plastic surgery and prosthetic devices
Zahid, Muhammad Jawad , Mavani, Parit T. , Awuah, Wireko Andrew , Alabdulrahman, Mohammad , Punukollu, Rachana , Kundu, Arnab , Mago, Arpit , Maher, Karam, Adebusoye, Favour Tope , Khan, Tehreem Naseer, Mavani, Parit , Adebusoye, Favour T , Punukollu, Rachana

Mayo Clinic

Health Science Reports | June 24, 2024 | Volume: 7 | Issue: 6 | Pages: No page available

10.1002/hsr2.2205 | PMID 38915353 Get It

Abstract Background and Aims The advent of 3D printing has revolutionized plastic surgery and prosthetic devices, providing personalized solutions for patients with traumatic injuries, deformities, and appearance‐related conditions. This review offers a comprehensive overview of 3D printing's applications, advantages, limitations, and future prospects in these fields. Methods A literature search was conducted in PubMed, Google Scholar, and Scopus for studies on 3D printing in plastic surgery. Results 3D printing has significantly contributed to personalized medical interventions, with benefits like enhanced design flexibility, reduced production time, and improved patient outcomes. Using computer‐aided design (CAD) software, precise models tailored to a patient's anatomy can be created, ensuring better fit, functionality, and comfort. 3D printing allows for intricate geometries, leading to improved aesthetic outcomes and patient‐specific prosthetic limbs and orthoses. The historical development of 3D printing, key milestones, and breakthroughs are highlighted. Recent progress in bioprinting and tissue engineering shows promising applications in regenerative medicine and transplantation. The integration of AI and automation with 3D printing enhances surgical planning and outcomes. Emerging trends in patient‐specific treatment planning and precision medicine are potential game‐changers. However, challenges like technical considerations, economic implications, and ethical issues exist. Addressing these challenges and advancing research in materials, design processes, and long‐term outcomes are crucial for widespread adoption. Conclusion The review underscores the increasing adoption of 3D printing in healthcare and its impact on plastic surgery and prosthetic devices. It emphasizes the importance of evaluating the current state and addressing knowledge gaps through future research to foster further advancements
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures
Cooley, Matthew A. , Schneider, Amber, Fritcher, Emily G. Barr , Milosevic, Dragana , Levy, Michael J. , Bridgeman, Amber R. , Martin, John A. , Petersen, Bret T. , Dayyeh, Barham K. Abu , Law, Ryan , Garimella, Vishal, Jenkins, Sarah M. , Yin, Jun, Roberts, Lewis R. , Kipp, Benjamin R. , Ferrándiz‐Pulido, Carla , Schneider, Amber R, Abu Dayyeh, Barham K , Storm, Andrew C , Law, Ryan J, Vargas, Eric J , Roberts, Lewis R , Kipp, Benjamin , Chandrasekhara, Vinay , Barr Fritcher, Emily G , Bridgeman, Amber R , Levy, Michael J. , Storm, Andrew C. , Vargas, Eric J. , Zemla, Tyler , Gores, Gregory J. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology | June 21, 2024 | Volume: 81 | Issue: 2 | Pages: 453-464

10.1097/hep.0000000000000970 | PMID 38905442 Get It

Background and Aims: Early identification of malignant biliary strictures (MBSs) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography. We aimed to evaluate the use of methylated DNA markers (MDMs) from biliary brushings to enhance MBS detection in a prospective cohort. Approach: Candidate MDMs were evaluated for their utility in MBS diagnosis through a series of discovery and validation phases. DNA was extracted from biliary brushing samples, quantified, bisulfite-converted, and then subjected to methylation-specific droplet digital polymerase chain reaction. Patients were considered to have no malignancy if the sampling was negative and there was no evidence of malignancy after 1 year or definitive negative surgical histopathology. Results: Fourteen candidate MDMs were evaluated in the discovery phase, with top-performing and new markers evaluated in the technical validation phase. The top 4 MDMs were TWIST1, HOXA1, VSTM2B, and CLEC11A, which individually achieved AUC values of 0.82, 0.81, 0.83, and 0.78, respectively, with sensitivities of 59.4%, 53.1%, 62.5%, and 50.0%, respectively, at high specificities for malignancy of 95.2%–95.3% for the final biologic validation phase. When combined as a panel, the AUC was 0.86, achieving 73.4% sensitivity and 92.9% specificity, which outperformed cytology and fluorescence in situ hybridization (FISH). Conclusions: The selected MDMs demonstrated improved performance characteristics for the detection of MBS compared to cytology and FISH. Therefore, MDMs should be considered viable candidates for inclusion in diagnostic testing algorithms.
Predictors of Durable Remission After Successful Surgery for Cushing Disease: Results From the Multicenter RAPID Registry
Tenhoeve, Sam , Evans, James, Collopy, Sarah , Delery, William , Pacione, Donato , Silverstein, Julie , Gardner, Paul A. , Rotman, Lauren E., Yuen, Kevin C.J. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Catalino, Michael P. , Little, Andrew S. , Karsy, Michael , Van Gompel, Jamie, Karsy, Michael , Findlay, Matthew C. , Alt, Jeremiah A. , Rennert, Robert C , Couldwell, William T. , Evans, James, Kim, Won Bae , Kim, Albert H. , Chicoine, Michael , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgery | June 21, 2024 | Volume: 95 | Issue: 4 | Pages: 761-769

10.1227/neu.0000000000003042 | PMID 39293794 Get It

BACKGROUND AND OBJECTIVE: Cushing disease (CD) affects mortality and quality of life along with limited long-term remission, underscoring the need to better identify recurrence risk. The identification of surgical or imaging predictors for CD remission after transsphenoidal surgery has yielded some inconsistent results and has been limited by single-center, single-surgeon, or meta-analyses studies. We sought to evaluate the multicenter Registry of Adenomas of the Pituitary and Related Disorders (RAPID) database of academic US pituitary centers to assess whether robust nonhormonal recurrence predictors could be elucidated. METHODS: Patients with treated CD from 2011 to 2023 were included. The perioperative and long-term characteristics of CD patients with and without recurrence were assessed using univariable and multivariable analyses. RESULTS: Of 383 patients with CD from 26 surgeons achieving postoperative remission, 288 (75.2%) maintained remission at last follow-up while 95 (24.8%) showed recurrence (median time to recurrence 9.99 ± 1.34 years). Patients with recurrence required longer postoperative hospital stays (5 ± 3 vs 4 ± 2 days, P = .002), had larger average tumor volumes (1.76 ± 2.53 cm 3 vs 0.49 ± 1.17 cm 3 , P = .0001), and more often previously failed prior treatment (31.1% vs 14.9%, P = .001) mostly being prior surgery. Multivariable hazard prediction models for tumor recurrence found younger age (odds ratio [OR] = 0.95, P = .002) and Knosp grade of 0 (OR = 0.09, reference Knosp grade 4, P = .03) to be protective against recurrence. Comparison of Knosp grade 0 to 2 vs 3 to 4 showed that lower grades had reduced risk of recurrence (OR = 0.27, P = .04). Other factors such as length of stay, surgeon experience, prior tumor treatment, and Knosp grades 1, 2, or 3 failed to reach levels of statistical significance in multivariable analysis. CONCLUSION: This multicenter study centers suggests that the strongest predictors of recurrence include tumor size/invasion and age. This insight can help with patient counseling and prognostication. Long-term follow-up is necessary for patients, and early treatment of small tumors may improve outcomes.
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Ni, Mingke , Saenen, Johan , Hoeksema, Wiert F. , Antiperovitch, Pavel , Arnaud, Marine , Tian, Shanshan, Sun, Bo , Estillore, John Paul , Wang, Ruiwu , Khan, Habib , Roston, Thomas M. , Mazzanti, Andrea , Giudicessi, John, Siontis, Konstantinos C. , Alak, Aiman, Acosta, J. Gabriel , Menon, Syamkumar M. Divakara, Tan, Nigel S. , Vivekanantham, Hari , Pandya, Tanvi, Cunningham, Jennifer , Gula, Lorne J. , Wong, Jorge , Amit, Guy , Scheinman, Melvin M. , Ackerman, Michael J. , Priori, Silvia G. , Sacher, Frédéric , Nof, Eyal , Glikson, Michael , Wilde, Arthur A.M. , Jensen, Henrik Kjærulf , Chen, S.R. Wayne , Roberts, Jason D. , Jensen, Henrik Kjærulf , Mazzanti, Andrea , Priori, Silvia , Dadon, Ziv , Ormerod, Julian O.M. , Tadros, Rafik , Christiansen, Morten Krogh , Steinberg, Christian , Giudicessi, John R. , Werf, Christian van der , Nazer, Babak , Krahn, Andrew D. , Gollob, Michael H. , Healey, Jeff S. , Glikson, Michael , Watkins, Hugh , Postema, Pieter G. , Belhassen, Bernard

Mayo Clinic

JAMA | June 20, 2024 | Volume: 332 | Issue: 3 | Pages: 204

10.1001/jama.2024.8599 | PMID 38900490 Get It

Importance Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS ( P < .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases ( P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.
Impact of Obesity on Timing of Tracheotomy: A Multi‐institutional Retrospective Study
Yousef, Andrew , Soliman, Shady , Panuganti, Bharat , Francis, David O. , Klebaner, Dasha, Asturias, Alicia , Alattar, Ali , Wood, Samuel , Terry, M. C. , Bryson, Paul C. , Tipton, Courtney B. , Zhao, Elise E. , Maria, Chloe Santa , Sung, C. Kwang , Lao, Wilson P. , Thompson, Jordan M. , Crawley, Brianna K. , Rosen, Sarah P. , Berezovsky, Anna , Hennesy, Theresa B. , Joseph, Ian T. , Sarhadi, Kamron, Kuhn, Maggie A. , Abdel‐Aty, Yassmeen , Kennedy, Maeve M. , Weissbrod, Philip A. , Soliman, Shady I , Pang, John , Wood, Samuel , Terry, Morgan , O'Rourke, Ashli , Grimm, David R , Sung, C K , Crawley, Brianna K , Rosen, Sarah , Berezovsky, Anna , Clary, Matthew S , Abdel-Aty, Yassmeen, Lott, David G , Weissbrod, Philip A , Solomon, Isaac, Grimm, David R. , Kupfer, Robbi A. , Clary, Matthew S. , Lott, David G.

Mayo Clinic

The Laryngoscope | June 19, 2024 | Volume: 134 | Issue: 11 | Pages: 4674-4681

10.1002/lary.31586 | PMID 38895915 Get It

Objective To examine the impact of increased body mass index (BMI) on (1) tracheotomy timing and (2) short‐term surgical complications requiring a return to the operating room and 30‐day mortality utilizing data from the Multi‐Institutional Study on Tracheotomy (MIST). Methods A retrospective analysis of patients from the MIST database who underwent surgical or percutaneous tracheotomy between 2013 and 2016 at eight institutions was completed. Unadjusted and adjusted logistic regression analyses were used to assess the impact of obesity on tracheotomy timing and complications. Results Among the 3369 patients who underwent tracheotomy, 41.0% were obese and 21.6% were morbidly obese. BMI was associated with higher rates of prolonged intubation prior to tracheotomy accounting for comorbidities, indication for tracheotomy, institution, and type of tracheostomy ( p = 0.001). Morbidly obese patients (BMI ≥35 kg/m 2 ) experienced a longer duration of intubation compared with patients with a normal BMI (median days intubated [IQR 25%–75%]: 11.0 days [7–17 days] versus 9.0 days [5–14 days]; p < 0.001) but did not have statistically higher rates of return to the operating room within 30 days ( p = 0.12) or mortality ( p = 0.90) on multivariable analysis. This same finding of prolonged intubation was not seen in overweight, nonobese patients when compared with normal BMI patients (median days intubated [IQR 25%–75%]: 10.0 days [6–15 days] versus 10.0 days [6–15 days]; p = 0.36). Conclusion BMI was associated with increased duration of intubation prior to tracheotomy. Although morbidly obese patients had a longer duration of intubation, there were no differences in return to the operating room or mortality within 30 days. Level of Evidence 3 Laryngoscope , 134:4674–4681, 2024
Outcomes of Device-detected Atrial High-rate Episodes in Patients with No Prior History of Atrial Fibrillation: A Systematic Review and Meta-analysis
Ahmed, Hasaan , Ismayl, Mahmoud , Palicherla, Anirudh , Kashou, Anthony H. , Dufani, Jalal, Anavekar, Nandan S., Aboeata, Ahmed, Kashou, Anthony , Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

Arrhythmia & Electrophysiology Review | June 18, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.15420/aer.2024.11 | PMID 38984148 Get It

Background: Outcomes of device-detected AF remain unclear in individuals without a prior history of AF. Methods: A meta-analysis was conducted to evaluate outcomes in individuals with no prior history of AF who experienced device-detected AF. Outcomes assessed were clinical AF, thromboembolism and all-cause mortality. A fixed-effects model was used to calculate RRs with 95% CI. Results: Compared to individuals who did not experience device-detected AF, those who did had increased risks of clinical AF (RR 3.33, 95% CI [1.99–5.57]; p<0.0001) and thromboembolic events (RR 2.21; 95% CI [1.72–2.85]; p<0.0001). The risk of all-cause mortality was similar between both groups (RR 1.19; 95% CI [0.95–1.49]; p=0.13). Subgroup analysis revealed an increased risk of thromboembolic events among device-detected AF ≥24 hours (RR 12.34; 95% CI [2.70–56.36]). Conclusion: While there is an increased risk of clinical AF and thromboembolism in individuals with device-detected AF, mortality was insignificant.
Racial, ethnic, and sex disparities in the utilization and outcomes of tricuspid valve surgery
Ahmed, Hasaan , Alkhouli, Mohamad , Ismayl, Mahmoud , Goldsweig, Andrew M. , Alkhouli, Mohamad , Guerrero, Mayra

Mayo Clinic

Annals of Medicine & Surgery | June 18, 2024 | Volume: 86 | Issue: 8 | Pages: 4368-4376

10.1097/ms9.0000000000002203 | PMID 39118698 Get It

Background: Data on racial/ethnic and sex disparities in the utilization and outcomes of tricuspid valve surgery (TVS) in the United States are scarce. The authors aimed to evaluate the impact of race/ethnicity and sex on the utilization and outcomes of TVS. Methods: The authors analyzed the National Inpatient Sample database from 2016 to 2020 to identify hospitalizations for TVS. Racial/ethnic and sex disparities in TVS outcomes were determined using logistic regression models. Results: Between 2016 and 2020, 19 395 hospitalizations for TVS were identified. The utilization rate (number of surgeries/100,000 hospitalizations) was lower in Black and Hispanic patients compared with White patients for surgical tricuspid valve repair (STVr) (331 versus 493 versus 634, P<0.01) and surgical tricuspid valve replacement (STVR) (312 versus 601 versus 728, P<0.01). Similarly, the utilization rate was lower for women compared with men for STVr (1021 versus 1364, P<0.01) and STVR (930 versus 1,316, P<0.01). Compared to White men undergoing TVS, all women had lower odds of acute kidney injury [adjusted odds ratio (aOR) 0.65, 95% CI 0.55–0.78] and higher odds of blood transfusion (aOR 1.30, 95% CI 1.07–1.59), and Black men had higher odds of blood transfusion (aOR 1.59, 95% CI 1.08–2.35). In-hospital mortality and other surgical complications were similar between all groups (all P>0.05). Conclusions: Significant racial/ethnic and sex disparities exist in the utilization of TVS in the United States. Further studies are needed to understand the reasons for these disparities and to identify effective strategies for their mitigation.
OTHR-20. MINIMALLY-INVASIVE MOLECULAR DIAGNOSIS OF INFILTRATING BRAINSTEM GLIOMAS THROUGH CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING
Hill, Katherine , Holle, Bridget M, Üçpınar, Burçin Ağrıdağ , DiNapoli, Sara , Riviere-Cazaux, Cécile , Burns, Terence, Haque, Sofia , Rosenblum, Marc K. , Doğan, Snjezana , Borsu, Laetitia , Ross, Dara S. , Zampieri, Caroline Barbosa, Donzelli, Maria, Lin, Andrew , Kramer, Kim , Souweidane, Mark M. , Arcila, Maria E. , Ladanyi, Marc , Mellinghoff, Ingo K. , Karajannis, Matthias A. , Miller, Alexandra , Mellinghoff, Ingo K , Karajannis, Matthias A , Vanderbilt, Chad , Giantini-Larsen, Alexandra , Hickman, Richard A. , Alano, Tina , Doe-Tetteh, Seyram A. , Young, Robert J. , Thakur, Sunitha B , Bale, Tejus , Benhamida, Jamal K. , Chang, Jason C. , Zampieri, Caroline Chaul de Lima Barbosa, Dunkel, Ira J. , Sait, Sameer Farouk , Greenfield, Jeffrey P. , Berger, Michael

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.690 Get It

Abstract BACKGROUND Accurate molecular diagnosis of infiltrating brainstem tumors, including diffuse midline gliomas and IDH mutant astrocytomas, is essential for prognostication and optimal therapy. Surgical biopsy of the brainstem carries risk of permanent neurological deficits and may yield insufficient or non-diagnostic tissue. We hypothesized that minimally invasive “liquid biopsy” analyzing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) could represent an alternative molecular diagnostic modality. METHODS We performed MSK-IMPACT, a New York State Department of Health authorized hybridization capture-based next-generation panel DNA sequencing clinical assay on 44 CSF samples from 37 unique patients with brainstem tumors. Ages at time of CSF collection ranged from 1–47 years (median: 29 years). For samples in which diagnostic alterations could not be detected, we performed a series of secondary analyses for known hotspot mutations such as H3F3A, IDH1/2, and BRAF, including manual review for mutant reads below the official clinical reporting threshold, as well as droplet digital PCR (ddPCR). RESULTS Among 44 samples included in this study, 10/44 (23%) samples had mutations detected by MSK-IMPACT using standard clinical calling criteria and 14 of the remaining 34 samples (41%) had supporting evidence of a diagnostically relevant mutation based on manual review. Testing by ddPCR was performed on 11 samples (based on DNA availability), uncovering 4 additional mutations. Overall positive diagnostic yield was 64% (28/44). In biopsied patients, CSF confirmed disease-defining mutations in 80% (16/20) of CSF samples, including H3F3A K28M (9/10; 90%) and IDH1/2 (5/6; 83%). Among 24 unbiopsied patients, a disease-defining mutation was identified in 60% (15/25) of CSF samples. CONCLUSIONS Analysis of CSF cfDNA in patients with brainstem tumors has a high diagnostic yield and obviates the need for tissue biopsy in a majority of patients. A tiered testing approach using next-generation sequencing and ddPCR assays helps maximize diagnostic information and sensitivity.
Living Kidney Donation: A Narrative Review of Mid- and Long-term Psychosocial Outcomes
Massey, Emma K. , Matas, Arthur J. , Rule, Andrew D.

Mayo Clinic

Transplantation | June 18, 2024 | Volume: 109 | Issue: 2 | Pages: 259-272

10.1097/tp.0000000000005094 | PMID 38886889 Get It

Living kidney donors make a significant contribution to alleviating the organ shortage. The aim of this article is to provide an overview of mid- and long-term (≥12 mo) living donor psychosocial outcomes and highlight areas that have been understudied and should be immediately addressed in both research and clinical practice. We conducted a narrative review by searching 3 databases. A total of 206 articles were included. Living donors can be divided into those who donate to an emotionally or genetically related person, the so-called directed donors, or to an emotionally or genetically unrelated recipient, the so-called nondirected donors. The most commonly investigated (bio)psychosocial outcome after living donation was health-related quality of life. Other generic (bio)psychological outcomes include specific aspects of mental health such as depression, and fatigue and pain. Social outcomes include financial and employment burdens and problems with insurance. Donation-specific psychosocial outcomes include regret, satisfaction, feelings of abandonment and unmet needs, and benefits of living kidney donation. The experience of living donation is complex and multifaceted, reflected in the co-occurrence of both benefits and burden after donation. Noticeably, no interventions have been developed to improve mid- or long-term psychosocial outcomes among living donors. We highlight areas for methodological improvement and identified 3 areas requiring immediate attention from the transplant community in both research and clinical care: (1) recognizing and providing care for the minority of donors who have poorer long-term psychosocial outcomes after donation, (2) minimizing donation-related financial burden, and (3) studying interventions to minimize long-term psychosocial problems.